AstraZeneca has launched a Phase III THARROS trial to evaluate the efficacy of its triple-combination inhaled therapy Breztri (budesonide / glycopyrronium / formoterol fumarate or BGF) in reducing severe cardiopulmonary outcomes in patients with chronic obstructive pulmonary disease (COPD)
Alkermes plc and Biogen Inc. announced positive topline results from EVOLVE-MS-2, a large, randomized, double-blind, five-week, Phase III study of...